132622-92-5Relevant articles and documents
Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library
Bingham, Patrick,Burke, Benjamin J.,Chen, Qiuxia,Cheng, Xuemin,Deng, Ya-Li,Dou, Dengfeng,Feng, Junli,Gallego, Gary M.,Gehring, Michael R.,Grant, Stephan K.,Greasley, Samantha,Harris, Anthony R.,Kung, Pei-Pei,Maegley, Karen A.,Meier, Jordan,Meng, Xiaoyun,Montano, Jose L.,Morgan, Barry A.,Naughton, Brigitte S.,Palde, Prakash B.,Paul, Thomas A.,Richardson, Paul,Sakata, Sylvie,Shaginian, Alex,Sonnenburg, William K.,Stewart, Albert E.,Subramanyam, Chakrapani,Timofeevski, Sergei,Wan, Jinqiao,Yan, Wen
supporting information, p. 1175 - 1184 (2020/07/04)
Two novel compounds were identified as Naa50 binders/inhibitors using DNA-encoded technology screening. Biophysical and biochemical data as well as cocrystal structures were obtained for both compounds (3a and 4a) to understand their mechanism of action. These data were also used to rationalize the binding affinity differences observed between the two compounds and a MLGP peptide-containing substrate. Cellular target engagement experiments further confirm the Naa50 binding of 4a and demonstrate its selectivity toward related enzymes (Naa10 and Naa60). Additional analogs of inhibitor 4a were also evaluated to study the binding mode observed in the cocrystal structures.
SUBSTITUTED OXOPYRIDINE DERIVATIVES
-
Paragraph 0575; 0576; 0577, (2019/01/04)
The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
A short diastereoselective synthesis of cis-(2S,4S) and cis-(2R,4R)-4-hydroxyprolines
Gajare, Vikas S.,Khobare, Sandip R.,Malavika,Rajana, Nagaraju,Venkateswara Rao,Syam Kumar
, p. 3743 - 3746 (2015/06/08)
A concise synthesis of (2R,4R)-4-hydroxyproline (1) and (2S,4S)-4-hydroxyproline (2) has been developed in enantiomerically pure form from commercially available starting materials with excellent diastereoselectivity. The tightly bound chelation controlled transition state formed during the 5-exo-tet ring closure reaction is assumed to be the origin of high diastereoselectivity.